Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 5, 2008, Pages 306-312

  Hara, Katsutoshi ^a   Suyama, Kazuaki ^a   Itoh, Hiroshi ^a   Nagashima, Satoru ^b  

^a Development and Medical Affairs Division   (Japan)

^b Shitoro Clinic   (Japan)

Author keywords

Aciclovir; Aldehyde dehydrogenase; CMMG; End stage renal disease (ESRD); Genetic polymorphisms; Hemodialysis; Pharmacokinetics; Valaciclovir

Indexed keywords

9 CARBOXYMETHOXYMETHYLGUANINE; ACICLOVIR; ALDEHYDE DEHYDROGENASE ISOENZYME 2; DRUG METABOLITE; UNCLASSIFIED DRUG; VALACICLOVIR; 9-CARBOXYMETHOXYMETHYLGUANINE; ALDEHYDE DEHYDROGENASE; ALDH2 PROTEIN, HUMAN; DRUG DERIVATIVE; GUANINE; PRODRUG; VALINE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HALF LIFE TIME; HEMODIALYSIS; HUMAN; JAPANESE; MALE; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; GENETICS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGED; ALDEHYDE DEHYDROGENASE; FEMALE; GUANINE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRODRUGS; RENAL DIALYSIS; VALINE;

EID: 58149291940     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.306     Document Type: Article

References (15)

1. Harada, S., Agarwal, D. P. and Goedde, H. W.: Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese. Lancet., 318: 982 (1981).
2. Wolff, P. H.: Ethnic differences in alcohol sensitivity. Science, 175: 449-450 (1972).
3. Harada, S.: Genetic polymorphism of alcohol metabolyzing enzymes and its implication to human ecology. J. Anthrop. Soc. Nippon, 99: 123-139 (1991).
4. Goedde, H. W., Agarwal, D. P., Fritze, G., Meier-Tackmann, D., Singh, S., Beckmann, G., Bhatia, K., Chen, L. Z., Fang, B., Lisker, R., Paik, Y. K., Rothhammer, F., Saha, N., Segal, B., Srivastava, L. M. and Czeizel, A.: Distribution of ADH2 and ALDH2 genotypes in different populations. Hum. Genet., 88: 344-346 (1992).
5. Enomoto, N., Takase, S., Yasuhara, M. and Takada, A.: Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin. Exp. Res., 15: 141-144 (1991).
6. Beutner, K. R., Friedman, D. J., Forszpaniak, C., Andersen, P. L. and Wood, M. J.: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother., 39: 1546-1553 (1995).
7. Bodsworth, N. J., Crooks, R. J., Borelli, S., Vejlsgaard, G., Paavonen, J., Worm, A. M., Uexkull, N., Esmann, J., Strand, A., Ingamells, A. J. and Gibb, A.: Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med., 73: 110-116 (1997).
8. Spruance, S. L., Jones, T. M., Blatter, M. M., Vargas-Cortes, M., Barber, J., Hill, J., Goldstein, D. and Schultz, M.: High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother., 47: 1072-1080 (2003).
9. de Miranda, P. and Blum, M. R.: Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother., (Suppl. B): 29-37 (1983).
10. de Miranda, P., Good, S. S., Laskin, O. L., Krasny, H. C., Connor, J. D. and Lietman, P. S.: Disposition of intravenous radioactive acyclovir. Clin. Pharmacol. Ther., 30: 662-672 (1981).
11. Blum, M. R., Liao S. H. and de Miranda, P.: Overview of acyclovir pharmacokinetic disposition in adults and children. Am. J. Med., 73: 186-192 (1982).
12. Chou, W. Y., Stewart, M. J., Carr, L. G., Zheng, D., Stewart, T. R., Williams, A., Pinaire, J. and Crabb, D. W.: An A/G polymorphism in the promoter of mitochondrial aldehyde dehydrogenase (ALDH2): effects of the sequence variant on transcription factor binding and promoter strength. Alcohol Clin. Exp. Res., 23: 963-968 (1999).
13. Spence, J. P., Liang, T., Eriksson, C. J., Taylor, R. E., Wall, T. L., Ehlers, C. L. and Carr, L. G.: Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations. Alcohol Clin. Exp. Res., 27: 1389-1394 (2003).
14. Kim, I., Chu, X.-Y., Kim, S., Provoda, C. J., Lee, K.-D., and Amidon, G. L.: Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Bio. Chem., 278: 25348-25356 (2003).
15. Hellden, A., Odar-Cederlof, I., Diener, P., Barkholt, L., Medin, C., Svensson, J. O., Sawe, J., and Stahle, L.: High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol. Dial. Transplant., 18: 1135-1141 (2003).